Head and neck squamous cell carcinoma (HNSCC), an aggressive malignancy, is
characterized by high morbidity and low survival rates with limited therapeutic options …

Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …

Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment …

Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …

Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a
negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD …

Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …

Background There are few effective treatment options for patients with recurrent or
metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …